Cure My Disease

Don't miss your cure!

 Log in / Sign up

Essential oils show promise for soothing chest infection symptoms

NCT ID NCT07518394

Symptom relief Sponsor: University of Sfax Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a dietary supplement with essential oils (Ubiotique) could reduce cough, phlegm, and fatigue in 105 adults visiting the emergency room with respiratory infections. Participants took either the supplement or a placebo three times daily for ten days and rated their symptoms. The goal was to see if the oils could safely ease symptoms faster than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

105 people

The number who actually took part.

Started

Mar 2023

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Consecutive patients presenting with acute cough and at least one of the following symptoms: sputum production, dyspnea, wheezing, or chest discomfort/pain * No alternative explanation for symptoms Exclusion Criteria: * Non-communicating patients * Pregnant patients * Patients with known allergy to study components

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Respiratory inflammation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Emergencies

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Respiratory inflammation

Contacts and locations

Locations

  • Habib Bourguiba University Hospital, Sfax

    Sfax, Sfax Governorate, 3029, Tunisia

More trials for these conditions

Other studies related to the condition(s) this trial covers.